These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18922158)

  • 21. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
    Patel C; Wyne KL; McGuire DK
    Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency.
    Janjgava S; Zerekidze T; Uchava L; Giorgadze E; Asatiani K
    Eur J Med Res; 2014 Oct; 19(1):56. PubMed ID: 25338765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Androgen deficit and diabetes].
    Cáp J
    Vnitr Lek; 2012 Mar; 58(3):228-31. PubMed ID: 22486290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pioglitazone: side effect and safety profile.
    Shah P; Mudaliar S
    Expert Opin Drug Saf; 2010 Mar; 9(2):347-54. PubMed ID: 20175701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive and negative effects of glitazones in carcinogenesis: experimental models vs. clinical practice.
    Bojková B; Orendáš P; Kubatka P; Péč M; Kassayová M; Kisková T; Kajo K
    Pathol Res Pract; 2014 Aug; 210(8):465-72. PubMed ID: 25023882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
    Nass CM; Blumenthal RS
    Am J Manag Care; 2000 Dec; 6(24 Suppl):S1247-56; quiz S1257-8. PubMed ID: 11142005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
    Sridhar S; Walia R; Sachdeva N; Bhansali A
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):454-9. PubMed ID: 22816533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance.
    Traish AM; Saad F; Guay A
    J Androl; 2009; 30(1):23-32. PubMed ID: 18772488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?
    Corona G; Mannucci E; Forti G; Maggi M
    Int J Androl; 2009 Oct; 32(5):431-41. PubMed ID: 19538523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?
    Saad F
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():52-9. PubMed ID: 23280867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relevant clinical and biological criteria for the diagnosis of androgen deficiency in the aging male (ADAM)].
    Seisen T; Rouprêt M; Gallais JL; Costa P
    Prog Urol; 2012 Jun; 22 Suppl 1():S21-6. PubMed ID: 22770497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug utilization, safety and clinical use of Actos and Avandia.
    Marks DH
    Int J Risk Saf Med; 2013 Jan; 25(1):39-51. PubMed ID: 23442297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of fractures with glitazones: a critical review of the evidence to date.
    Bodmer M; Meier C; Kraenzlin ME; Meier CR
    Drug Saf; 2009; 32(7):539-47. PubMed ID: 19530741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.